MENU
ZNTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Zentalis Pharmaceuticals (ZNTL) Earnings Date & Reports
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more
A.I. Advisor
published Earnings
ZNTL is expected to report earnings to fall 4.00% to -47 cents per share on August 12
Q2'26
Est.
$-0.48
Q1'26
Est.
$-0.50
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.16
Q2'25
Beat
by $0.17
The last earnings report on May 12 showed earnings per share of -50 cents, meeting the estimate of -50 cents. With 302.44K shares outstanding, the current market capitalization sits at 261.97M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer
Industry Biotechnology
Profile
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com